Top

Published in:

Open Access 01-04-2015 | Bone and Diabetes (AV Schwartz and P Vestergaard, Section Editors)

Diabetes, Diabetic Complications, and Fracture Risk

Authors: Ling Oei, Fernando Rivadeneira, M. Carola Zillikens, Edwin H. G. Oei

Published in: Current Osteoporosis Reports | Issue 2/2015

Abstract

Diabetes and osteoporosis are both common diseases with increasing prevalences in the aging population. There is increasing evidence corroborating an association between diabetes mellitus and bone. This review will discuss the disease complications of diabetes on the skeleton, highlighting findings from epidemiological, molecular, and imaging studies in animal models and humans. Compared to control subjects, decreased bone mineral density (BMD) has been observed in type 1 diabetes mellitus, while on average, higher BMD has been found in type 2 diabetes; nonetheless, patients with both types of diabetes are seemingly at increased risk of fractures. Conventional diagnostics such as DXA measurements and the current fracture risk assessment tool (FRAX) risk prediction algorithm for estimating risk of osteoporotic fractures are not sufficient in the case of diabetes. A deterioration in bone microarchitecture and an inefficient distribution of bone mass with insufficiency of repair and adaptation mechanisms appear to be factors of relevance. A highly complex and heterogeneous molecular pathophysiology underlies diabetes-related bone disease, involving hormonal, immune, and perhaps genetic pathways. The detrimental effects of chronically elevated glucose levels on bone should be added to the more well-known complications of diabetes.

1.••

Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18(4):427–44. This meta-analysis was among the first to distil the evidence that hip fracture risk is increased in both type 1 and type 2 diabetes mellitus, whereas bone mineral density is increased in type 2 diabetes mellitus and decreased in type 1 diabetes mellitus.PubMed

van Daele PL, Stolk RP, Burger H, Algra D, Grobbee DE, Hofman A, et al. Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med. 1995;122(6):409–14.PubMed

Kao WH, Kammerer CM, Schneider JL, Bauer RL, Mitchell BD. Type 2 diabetes is associated with increased bone mineral density in Mexican-American women. Arch Med Res. 2003;34(5):399–406.PubMed

Majima T, Komatsu Y, Yamada T, Koike Y, Shigemoto M, Takagi C, et al. Decreased bone mineral density at the distal radius, but not at the lumbar spine or the femoral neck, in Japanese type 2 diabetic patients. Osteoporos Int. 2005;16(8):907–13.PubMed

Yaturu S, Humphrey S, Landry C, Jain SK. Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. Med Sci Monit. 2009;15(1):CR5–9.PubMed

6.•

Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012;27(5):319–32. Systematic review containing an updated meta-analysis and meta-regression which showed that individuals with type 2 diabetes have generally higher bone mineral density throughout the skeleton, which is again under the influence of multiple factors.PubMedCentralPubMed

Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495–505.PubMed

8.••

Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305(21):2184–92. Data from three large prospective observational studies demonstrated that current risk prediction based on femoral neck bone mineral density and FRAX score underestimate fracture risk among older adults with type 2 diabetes mellitus.PubMedCentralPubMed

de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005;16(12):1713–20.PubMed

10.

Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, et al. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2012;27(2):301–8.PubMed

11.

Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009;24(4):702–9.PubMed

12.

Kilpadi KL, Eldabaje R, Schmitz JE, Ehler B, Thames TA, Joshi AP, et al. Type 2 diabetes is associated with vertebral fractures in a sample of clinic- and hospital-based Latinos. J Immigr Minor Health. 2014;16(3):440–9.PubMed

13.

Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med. 2005;165(14):1612–7.PubMed

14.

Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86(1):32–8.PubMed

15.

Barrett-Connor E, Holbrook TL. Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA. 1992;268(23):3333–7.PubMed

16.

Ruiter R, Oei L, Visser LE, Peltenburg HG, Hofman A, Zillikens MC, et al. The effect of thiazide and loop diuretics on urinary levels of free deoxypyridinoline: an osteoclastic bone-resorption marker. J Clin Pharm Ther. 2013;38(3):225–9.PubMed

17.

Aung K, Htay T. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev. 2011;10, CD005185.PubMed

18.

Schoofs MW, van der Klift M, Hofman A, de Laet CE, Herings RM, Stijnen T, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med. 2003;139(6):476–82.PubMed

19.

Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95(2):592–600.PubMedCentralPubMed

20.

Schwartz AV, Hillier TA, Sellmeyer DE, Resnick HE, Gregg E, Ensrud KE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care. 2002;25(10):1749–54.PubMed

21.

Schwartz AV, Vittinghoff E, Sellmeyer DE, Feingold KR, de Rekeneire N, Strotmeyer ES, et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 2008;31(3):391–6.PubMedCentralPubMed

22.

Ivers RQ, Cumming RG, Mitchell P, Peduto AJ. Diabetes and risk of fracture: the Blue Mountains Eye Study. Diabetes Care. 2001;24(7):1198–203.PubMed

23.

Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014 Jan;37 Suppl 1:S81–90.

24.••

Oei L, Zillikens MC, Dehghan A, Buitendijk GH, Castano-Betancourt MC, Estrada K, et al. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study. Diabetes Care. 2013;36(6):1619–28. Prospective population-based study showing that poor glycemic control is associated with higher fracture risk, higher bone mineral density, and thicker femoral cortices in narrower bones.PubMedCentralPubMed

25.••

Schneider AL, Williams EK, Brancati FL, Blecker S, Coresh J, Selvin E. Diabetes and risk of fracture-related hospitalization: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2013;36(5):1153–8. Participants with diabetes from the Atherosclerosis Risk in Communities (ARIC) Study had an increased risk of fracture, where persons treated with insulin and those with higher hemoglobin A1c had the highest risk.PubMedCentralPubMed

26.

Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Combination of obesity with hyperglycemia is a risk factor for the presence of vertebral fractures in type 2 diabetic men. Calcif Tissue Int. 2008;83(5):324–31.PubMed

27.

Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223–34.PubMed

28.

Hernandez CJ, Tang SY, Baumbach BM, Hwu PB, Sakkee AN, van der Ham F, et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. Bone. 2005;37(6):825–32.PubMedCentralPubMed

29.

Wang X, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone. 2002;31(1):1–7.PubMed

30.

Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318(20):1315–21.PubMed

31.

Viguet-Carrin S, Roux JP, Arlot ME, Merabet Z, Leeming DJ, Byrjalsen I, et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone. 2006;39(5):1073–9.PubMed

32.

Saito M, Fujii K, Soshi S, Tanaka T. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int. 2006;17(7):986–95.PubMed

33.

Saito M, Fujii K, Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int. 2006;79(3):160–8.PubMed

34.•

Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(3):1013–9. Case–control study showing increased serum levels of pentosidine in women with vertebral fractures than in those without vertebral fractures. Replication of these results and more understanding of the advanced glycation end product (AGE) pathophysiology will be necessary.PubMed

35.

Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care. 2009;32(12):2263–8.PubMedCentralPubMed

36.

Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008;22(5):1572–80.PubMed

37.

Kalea AZ, Reiniger N, Yang H, Arriero M, Schmidt AM, Hudson BI. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J. 2009;23(6):1766–74.PubMedCentralPubMed

38.

Zhou Z, Immel D, Xi CX, Bierhaus A, Feng X, Mei L, et al. Regulation of osteoclast function and bone mass by RAGE. J Exp Med. 2006;203(4):1067–80.PubMedCentralPubMed

39.

Pun KK, Lau P, Ho PW. The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. J Bone Miner Res. 1989;4(6):853–62.PubMed

40.

Kawai M, Rosen CJ. Insulin-like growth factor-I and bone: lessons from mice and men. Pediatr Nephrol. 2009;24(7):1277–85.PubMed

41.

Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int. 2011;22(4):1191–8.PubMed

42.

Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int. 2007;18(12):1675–81.PubMed

43.•

Thrailkill K, Bunn RC, Lumpkin Jr C, Wahl E, Cockrell G, Morris L, et al. Loss of insulin receptor in osteoprogenitor cells impairs structural strength of bone. J Diabetes Res. 2014;2014:703589. Osteoprogenitor-selective (osterix-Cre) ablation of the insulin receptor in mice yields a skeletal phenotype with growth restriction, illustrating that insulin receptor expression in osteoblasts is critically important for bone development and maintenance of structural integrity.PubMedCentralPubMed

44.

Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142(2):309–19.PubMedCentralPubMed

45.

Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142(2):296–308.PubMedCentralPubMed

46.

Booth SL, Centi A, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol. 2013;9(1):43–55.PubMed

47.

Rached MT, Kode A, Silva BC, Jung DY, Gray S, Ong H, et al. FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J Clin Invest. 2010;120(1):357–68.PubMedCentralPubMed

48.••

Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, et al. Increased bone formation in osteocalcin-deficient mice. Nature. 1996;382(6590):448–52. Osteocalcin-deficient mice develop glucose intolerance and insulin resistance but, at the same time, a higher bone mass and improved functional quality.PubMed

49.•

Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab. 1997;82(3):719–24. Large prospective population-based cohort study in elderly women replicating the observation that higher levels of circulating undercarboxylated osteocalcin, but not total osteocalcin, predict hip fracture risk independently of femoral neck bone mineral density.PubMed

50.••

Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest. 1993;91(4):1769–74. Prospective cohort study in 195 institutionalized elderly women. The risk of hip fracture was increased in women with elevated undercarboxylated osteocalcin. The level of undercarboxylated osteocalcin was negatively correlated with 25OH-vitamin D, and 1 year of calcium/vitamin D2 treatment decreased undercarboxylated osteocalcin, yet no effects on fracture end points were reported.PubMedCentralPubMed

51.

Lian JB, Stein GS, Stein JL, van Wijnen AJ. Regulated expression of the bone-specific osteocalcin gene by vitamins and hormones. Vitam Horm. 1999;55:443–509.PubMed

52.

Bolton-Smith C, McMurdo ME, Paterson CR, Mole PA, Harvey JM, Fenton ST, et al. Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. J Bone Miner Res. 2007;22(4):509–19.PubMed

53.

Deyl Z, Adam M. Evidence for vitamin D dependent gamma-carboxylation in osteocalcin related proteins. Biochem Biophys Res Commun. 1983;113(1):294–300.PubMed

54.

Jayalath RW, Mangan SH, Golledge J. Aortic calcification. Eur J Vasc Endovasc Surg. 2005;30(5):476–88.PubMed

55.

Kim KJ, Kim KM, Park KH, Choi HS, Rhee Y, Lee YH, et al. Aortic calcification and bone metabolism: the relationship between aortic calcification, BMD, vertebral fracture, 25-hydroxyvitamin D, and osteocalcin. Calcif Tissue Int. 2012;91(6):370–8.PubMed

56.

Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008;34(1):2–11.PubMed

57.

Kanabrocki EL, Hermida RC, Wright M, Young RM, Bremner FW, Third JL, et al. Circadian variation of serum leptin in healthy and diabetic men. Chronobiol Int. 2001;18(2):273–83.PubMed

58.

Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem. 2002;85(4):825–36.PubMed

59.

Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Hartzell D, Baile CA. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res. 2005;20(6):994–1001.PubMed

60.

Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept. 2000;92(1–3):73–8.PubMed

61.

Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol. 2002;175(2):405–15.PubMed

62.

Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, et al. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002;17(2):200–9.PubMed

63.

Di Monaco M, Vallero F, Di Monaco R, Mautino F, Cavanna A. Fat body mass, leptin and femur bone mineral density in hip-fractured women. J Endocrinol Invest. 2003;26(12):1180–5.PubMed

64.

Zoico E, Zamboni M, Adami S, Vettor R, Mazzali G, Tosoni P, et al. Relationship between leptin levels and bone mineral density in the elderly. Clin Endocrinol (Oxf). 2003;59(1):97–103.

65.

Jurimae J, Kums T, Jurimae T. Adipocytokine and ghrelin levels in relation to bone mineral density in physically active older women: longitudinal associations. Eur J Endocrinol. 2009;160(3):381–5.PubMed

66.

Schett G, Kiechl S, Bonora E, Redlich K, Woloszczuk W, Oberhollenzer F, et al. Serum leptin level and the risk of nontraumatic fracture. Am J Med. 2004;117(12):952–6.PubMed

67.

Barbour KE, Zmuda JM, Boudreau R, Strotmeyer ES, Horwitz MJ, Evans RW, et al. Adipokines and the risk of fracture in older adults. J Bone Miner Res. 2011;26(7):1568–76.PubMedCentralPubMed

68.

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930–5.PubMed

69.

Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone. 2004;35(4):842–9.PubMed

70.

Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 2006;21(10):1648–56.PubMed

71.

Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005;331(2):520–6.PubMed

72.

Richards JB, Valdes AM, Burling K, Perks UC, Spector TD. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab. 2007;92(4):1517–23.PubMed

73.

Delhanty PJ, van der Eerden BC, van Leeuwen JP. Ghrelin and bone. Biofactors. 2014;40(1):41–8.PubMed

74.

Biver E, Salliot C, Combescure C, Gossec L, Hardouin P, Legroux-Gerot I, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(9):2703–13.PubMed

75.

Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13(6):465–76.PubMed

76.

Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E, Oberlin F. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation. 1999;99(16):2221–2.PubMed

77.

Kahn SE, Zinman B, Haffner SM, O’Neill MC, Kravitz BG, Yu D, et al. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes. 2006;55(8):2357–64.PubMed

78.

de Pablo P, Cooper MS, Buckley CD. Association between bone mineral density and C-reactive protein in a large population-based sample. Arthritis Rheum. 2012;64(8):2624–31.PubMed

79.

Koh JM, Khang YH, Jung CH, Bae S, Kim DJ, Chung YE, et al. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos Int. 2005;16(10):1263–71.PubMed

80.•

Oei L, Campos-Obando N, Dehghan A, Oei EH, Stolk L, van Meurs JB, et al. Dissecting the relationship between high-sensitivity serum C-reactive protein and increased fracture risk: the Rotterdam Study. Osteoporos Int. 2014;25(4):1247–54. Serum high-sensitivity C-reactive protein is associated with fracture risk and lower bending strength, yet there is no evidence so far for this relationship being causal.PubMed

81.

Pasco JA, Kotowicz MA, Henry MJ, Nicholson GC, Spilsbury HJ, Box JD, et al. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA. 2006;296(11):1353–5.PubMed

82.

Rolland T, Boutroy S, Vilayphiou N, Blaizot S, Chapurlat R, Szulc P. Poor trabecular microarchitecture at the distal radius in older men with increased concentration of high-sensitivity C-reactive protein—the STRAMBO study. Calcif Tissue Int. 2012;90(6):496–506.PubMed

83.

Kanai A, Kawamura T, Umemura T, Nagashima M, Nakamura N, Nakayama M, et al. Association between future events of brain infarction and soluble levels of intercellular adhesion molecule-1 and C-reactive protein in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;82(2):157–64.PubMed

84.

Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, Zhang JS, et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2006;5:27.PubMedCentralPubMed

85.

Cox AJ, Agarwal S, MH D, Carr JJ, Freedman BI, Bowden DW. C-reactive protein concentration predicts mortality in type 2 diabetes: the Diabetes Heart Study. Diabet Med. 2012;29(6):767–70.PubMed

86.

Jin C, Lu L, Zhang RY, Zhang Q, Ding FH, Chen QJ, et al. Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus. Clin Chim Acta. 2009;408(1–2):45–9.PubMed

87.

Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.PubMed

88.

Sorisky A. Molecular links between obesity and cardiovascular disease. Am J Ther. 2002;9(6):516–21.PubMed

89.

Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102(18):2165–8.PubMed

90.

Kodama K, Horikoshi M, Toda K, Yamada S, Hara K, Irie J, et al. Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes. Proc Natl Acad Sci U S A. 2012;109(18):7049–54.PubMedCentralPubMed

91.•

Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44(5):491–501. Genome-wide association study meta-analysis that identified loci for bone mineral density and fracture risk, among which the 4q22.1 locus containing osteopontin.PubMedCentralPubMed

92.

Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, Richards JB, et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet. 2009;41(11):1199–206.PubMedCentralPubMed

93.

Duncan EL, Danoy P, Kemp JP, Leo PJ, McCloskey E, Nicholson GC, et al. Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet. 2011;7(4):e1001372.PubMedCentralPubMed

94.

Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008;358(22):2355–65.PubMed

95.

Hunter GK, O’Young J, Grohe B, Karttunen M, Goldberg HA. The flexible polyelectrolyte hypothesis of protein-biomineral interaction. Langmuir. 2010;26(24):18639–46.PubMed

96.

Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, et al. Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford). 2008;47(12):1775–9.

97.

Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin—a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A. 1990;87(12):4473–5.PubMedCentralPubMed

98.

Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19(5–6):333–45.PubMed

99.

Franzen A, Hultenby K, Reinholt FP, Onnerfjord P, Heinegard D. Altered osteoclast development and function in osteopontin deficient mice. J Orthop Res. 2008;26(5):721–8.PubMed

100.

Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest. 2007;117(10):2877–88.PubMedCentralPubMed

101.•

Oei L, Hsu YH, Styrkarsdottir U, Eussen BH, de Klein A, Peters MJ, et al. A genome-wide copy number association study of osteoporotic fractures points to the 6p25.1 locus. J Med Genet. 2014;51(2):122–31. Fracture associated deletions in the 6p25.1 locus may influence the regulatory region of peroxisomal D3, D2-enoylCoA isomerase (PECI) which has been suggested as an auto-antigen in diabetes.PubMed

102.

Mountz JD, Edwards 3rd CK. Murine models of autoimmunity: T-cell and B-cell defects. Curr Opin Rheumatol. 1992;4(5):612–20.PubMed

103.

Billings LK, Hsu YH, Ackerman RJ, Dupuis J, Voight BF, Rasmussen-Torvik LJ, et al. Impact of common variation in bone-related genes on type 2 diabetes and related traits. Diabetes. 2012;61(8):2176–86.PubMedCentralPubMed

104.

Ekholm E, Hankenson KD, Uusitalo H, Hiltunen A, Gardner H, Heino J, et al. Diminished callus size and cartilage synthesis in alpha 1 beta 1 integrin-deficient mice during bone fracture healing. Am J Pathol. 2002;160(5):1779–85.PubMedCentralPubMed

105.

Petit MA, Paudel ML, Taylor BC, Hughes JM, Strotmeyer ES, Schwartz AV, et al. Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J Bone Miner Res. 2010;25(2):285–91.PubMedCentralPubMed

106.

Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause. N Engl J Med. 2003;349(4):327–34.PubMed

107.

Seeman E. Clinical review 137: sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab. 2001;86(10):4576–84.PubMed

108.

Sayers A, Lawlor DA, Sattar N, Tobias JH. The association between insulin levels and cortical bone: findings from a cross-sectional analysis of pQCT parameters in adolescents. J Bone Miner Res. 2012;27(3):610–8.PubMedCentralPubMed

109.••

Burghardt AJ, Issever AS, Schwartz AV, Davis KA, Masharani U, Majumdar S, et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95(11):5045–55. A high-resolution peripheral quantitative computed tomography (HR-pQCT) pilot study demonstrating that type 2 diabetes mellitus patients have higher trabecular volumetric bone mineral density adjacent to the cortex, possibly reflecting an inefficient redistribution of bone mass, characterized by loss of intracortical bone offset by an elevation in trabecular bone density.PubMedCentralPubMed

110.••

Patsch JM, Burghardt AJ, Yap SP, Baum T, Schwartz AV, Joseph GB, et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013;28(2):313–24. A medium-size imaging study comparing peripheral bone microarchitecture and strength between postmenopausal women with type 2 diabetes with and without fragility fractures, implicating a part for deficits in cortical bone quality.PubMedCentralPubMed

111.

Pothuaud L, Carceller P, Hans D. Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. Bone. 2008;42(4):775–87.PubMed

112.

Leslie WD, Aubry-Rozier B, Lamy O, Hans D. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab. 2013;98(2):602–9.PubMed

113.

Patsch JM, Li X, Baum T, Yap SP, Karampinos DC, Schwartz AV, et al. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J Bone Miner Res. 2013;28(8):1721–8.PubMedCentralPubMed

114.

Baum T, Yap SP, Karampinos DC, Nardo L, Kuo D, Burghardt AJ, et al. Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus? J Magn Reson Imaging. 2012;35(1):117–24.PubMedCentralPubMed

115.

Bridges D, Randall C, Hansma PK. A new device for performing reference point indentation without a reference probe. Rev Sci Instrum. 2012;83(4):044301.PubMedCentralPubMed

116.

Randall C, Bridges D, Guerri R, Nogues X, Puig L, Torres E, et al. Applications of a new handheld reference point indentation instrument measuring bone material strength. J Med Device. 2013;7(4):410051–6.PubMed

117.

Diez-Perez A, Guerri R, Nogues X, Caceres E, Pena MJ, Mellibovsky L, et al. Microindentation for in vivo measurement of bone tissue mechanical properties in humans. J Bone Miner Res. 2010;25(8):1877–85.PubMedCentralPubMed

118.

Guerri-Fernandez RC, Nogues X, Quesada Gomez JM, Torres Del Pliego E, Puig L, Garcia-Giralt N, et al. Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res. 2013;28(1):162–8.PubMed

119.••

Farr JN, Drake MT, Amin S, Melton LJ, 3rd, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2013 Oct;1. In vivo microindentation testing of the tibia was applied in patients with type 2 diabetes finding reduced serum markers of bone turnover and lower bone material strength at the tibia than age-matched controls without diabetes.

120.

Blakytny R, Spraul M, Jude EB. Review: the diabetic bone: a cellular and molecular perspective. Int J Low Extrem Wounds. 2011;10(1):16–32.PubMed

121.

Taniguchi T, Matsumoto T, Shindo H. Changes of serum levels of osteocalcin, alkaline phosphatase, IGF-I and IGF-binding protein-3 during fracture healing. Injury. 2003;34(7):477–9.PubMed

122.

Akesson K, Vergnaud P, Delmas PD, Obrant KJ. Serum osteocalcin increases during fracture healing in elderly women with hip fracture. Bone. 1995;16(4):427–30.PubMed

123.

Nyman MT, Paavolainen P, Forsius S, Lamberg-Allardt C. Clinical evaluation of fracture healing by serum osteocalcin and alkaline phosphatase. Ann Chir Gynaecol. 1991;80(3):289–93.PubMed

124.

Hamann C, Picke AK, Campbell GM, Balyura M, Rauner M, Bernhardt R, et al. Effects of parathyroid hormone on bone mass, bone strength, and bone regeneration in male rats with type 2 diabetes mellitus. Endocrinology. 2014;155(4):1197–206.PubMed

125.

Bauer DC. Calcium supplements and fracture prevention. N Engl J Med. 2014;370(4):387–8.PubMed

126.

Bolland MJ, Grey A, Avenell A, Reid IR. Calcium supplements increase risk of myocardial infarction. J Bone Miner Res. 2014 Sep;11.

127.

Lewis JR, Radavelli-Bagatini S, Rejnmark L, Chen JS, Simpson JM, Lappe JM, et al. Response to “calcium supplements increase risk of myocardial infarction”. J Bone Miner Res. 2014 Nov;21.

128.

Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691.PubMedCentralPubMed

129.

Michaelsson K, Melhus H, Warensjo Lemming E, Wolk A, Byberg L. Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. BMJ. 2013;346:f228.PubMedCentralPubMed

130.

Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ, Anderson GL, et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporos Int. 2013;24(2):567–80.PubMedCentralPubMed

131.

Lewis JR, Radavelli-Bagatini S, Rejnmark L, Chen JS, Simpson JM, Lappe JM, et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res. 2015;30(1):165–75.PubMed

132.

Gonnelli S, Caffarelli C, Giordano N, Nuti R. The prevention of fragility fractures in diabetic patients. Aging Clin Exp Res. 2014 Jul;25.

Title: Diabetes, Diabetic Complications, and Fracture Risk
Authors: Ling Oei
Fernando Rivadeneira
M. Carola Zillikens
Edwin H. G. Oei
Publication date: 01-04-2015
Publisher: Springer US
Published in: Current Osteoporosis Reports / Issue 2/2015
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-015-0260-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Diabetes, Diabetic Complications, and Fracture Risk

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss

Hyperphosphatemic Familial Tumoral Calcinosis: Genetic Models of Deficient FGF23 Action

Cx43 and Mechanotransduction in Bone

Defective Skeletal Mineralization in Pediatric CKD

Diet, Gut Microbiome, and Bone Health

Osteocyte Shape and Mechanical Loading